Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Daniel M. Bradbury Joins Corcept Therapeutics, Inc. (CORT) Board Of Directors

|Includes: Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics announced that Daniel M. Bradbury has been appointed to the company's Board of Directors.

"We are pleased that Dan has joined our Board," said Corcept's Chief Executive Officer, Joseph K. Belanoff, M.D. "His long experience with every aspect of the biotech industry, from drug discovery through approval and product launch, will be invaluable as we commercialize Korlymâ„¢ for Cushing's syndrome, continue our Phase 3 trial of mifepristone for the treatment of the psychotic features of psychotic depression and pursue development of our next-generation GR-II antagonists."

Mr. Bradbury has over 30 years of experience in the biotechnology and pharmaceutical industries. He served as CEO of Amylin Pharmaceuticals from March 2007 until August 2012, when it was acquired by Bristol-Myers Squibb Company. He served on the company's board of directors and served on its Finance and Risk Management Committee. In his time at Amylin, Mr. Bradbury served as President (2006-2007), Chief Operating Officer (2003-2006), and Executive Vice President (2000-2003).

Before joining Amylin, Mr. Bradbury worked at SmithKline Beecham Pharmaceuticals for 10 years in various marketing and sales roles. He also serves on the board of directors of Illumina, Inc., Geron Corporation, and Castle Biosciences, Inc., as well as the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee.

"This is an exciting time for Corcept," said Mr. Bradbury. "Its platform of cortisol receptor antagonists, of which I believe Korlym for endogenous Cushing's syndrome is just the first, could generate treatments for many severe illnesses." He added, "I look forward to helping bring those medicines to patients."

Corcept Therapeutics is a pharmaceutical company engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders.

Please see disclaimer on the MissionIR website